Following two failed attempts at an IPO, EpiCept has now gone down the M&A route to gain a public listing by agreeing to merge with the now struggling Maxim Pharmaceuticals. This feature considers the recent activities and issues surrounding the two companies that have driven them to enter into such a transaction.